Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and

M E Brousseau1, M Bodzioch, E J Schaefer

  • 1The Lipid Metabolism Laboratory, JM-USDA Human Nutrition Research Center on Aging at Tufts, Boston, MA, USA.

Atherosclerosis
|March 21, 2001
PubMed

Insights

Common variants in the ATP-binding cassette transporter 1 (ABCA1) gene were studied for their effect on HDL cholesterol levels and coronary heart disease (CHD) risk. The G3456C variant showed an association with increased CHD risk in men with low HDL-C.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Lipid Metabolism

Background:

  • Low HDL cholesterol is a common lipid abnormality linked to premature coronary heart disease (CHD).
  • Mutations in the ATP-binding cassette transporter 1 (ABCA1) gene cause Tangier disease, a rare disorder associated with low HDL-C and increased CHD risk.

Purpose of the Study:

  • To investigate whether common variants in the ABCA1 gene coding sequence influence plasma HDL-C levels and CHD risk in the general population.

Main Methods:

  • Examined allele frequencies of three common ABCA1 variants (G596A, A2589G, G3456C) in men from the VA-HIT and Framingham Offspring Study (FOS).
  • Assessed the association of these variants with plasma HDL-C concentrations and CHD endpoints.

Main Results:

  • Allele frequencies for the variants differed between the VA-HIT and FOS populations (P<0.03).
  • None of the ABCA1 variants were significantly associated with plasma HDL-C levels in either cohort.
  • The G3456C variant was significantly associated with an increased risk of CHD endpoints in the VA-HIT cohort.

Conclusions:

  • Common ABCA1 variants do not appear to significantly impact HDL-C levels in the general population.
  • The ABCA1 G3456C variant may play a role in the predisposition to premature CHD observed in certain populations.

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...